Journal Article

<i>In vitro</i> antistaphylococcal activity of dalbavancin, a novel glycopeptide

Sara Lopez, Corinne Hackbarth, Gabriella Romanò, Joaquim Trias, Daniela Jabes and Beth P. Goldstein

in Journal of Antimicrobial Chemotherapy

Volume 55, issue suppl_2, pages ii21-ii24
Published in print March 2005 | ISSN: 0305-7453
Published online March 2005 | e-ISSN: 1460-2091 | DOI: http://dx.doi.org/10.1093/jac/dki007
In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide

More Like This

Show all results sharing these subjects:

  • Medical Oncology
  • Critical Care

GO

Show Summary Details

Preview

Objectives: Dalbavancin is a novel, semi-synthetic glycopeptide antibiotic. The aim of this study was to further explore its activity against staphylococci.

Methods: The bactericidal activity of dalbavancin was studied using MBC and time–kill methods. The potential for resistance to dalbavancin was examined using single-step and serial-passage experiments.

Results: Dalbavancin was bactericidal against methicillin-susceptible and -resistant Staphylococcus aureus, in both the presence and absence of human serum. No resistance was seen with any isolate tested. After serial passage, bacterial populations were more homogeneous in their susceptibility to dalbavancin than to vancomycin or teicoplanin.

Conclusion: Dalbavancin is bactericidal for staphylococci. Resistance to this semi-synthetic glycopeptide is not readily developed in vitro.

Keywords: bactericidal activity; resistance; staphylococci

Journal Article.  0 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.